IGF-1 DES, or des(1-3)IGF-1, is a truncated insulin-like growth factor 1 missing its first three N-terminal amino acids, which strips most of its affinity for IGF-binding proteins and leaves it more active at the receptor. Research peptides like it carry no FDA approval and may be restricted. Below you'll find reported dosing, reconstitution, safety, and legal status. Educational only, not medical advice.
Ballard FJ, et al. Natural and synthetic forms of IGF-1 and the potent derivative destripeptide IGF-1: biological activities and receptor binding. Biochem Biophys Res Commun. 1987;149(2):398-404. https://pubmed.ncbi.nlm.nih.gov/2962574/
Ross M, et al. IGF-binding proteins inhibit the biological activities of IGF-1 and IGF-2 but not des-(1-3)-IGF-1. Biochem J. 1989;258(1):267-272. https://pubmed.ncbi.nlm.nih.gov/2539101/
Ballard FJ, et al. Des(1-3)IGF-I: a truncated form of insulin-like growth factor-I. Int J Biochem Cell Biol. 1996;28(10):1085-1087. https://pubmed.ncbi.nlm.nih.gov/8930132/
Tomas FM, et al. IGF-I variants which bind poorly to IGF-binding proteins show more potent and prolonged hypoglycaemic action than native IGF-I in pigs and marmoset monkeys. J Endocrinol. 1997;155(2):377-386. https://pubmed.ncbi.nlm.nih.gov/9415072/
PepWise is an informational and educational tracking tool, not medical advice and not a medical device. IGF-1 DES may be experimental, restricted, or prescription-only; many research peptides are not FDA-approved. Consult a licensed healthcare provider before starting, changing, or stopping any protocol. Operated by STC Consulting, Inc.
